There are now over 30 unique therapeutic entities (and countless different products!) to treat hyperglycemia in patients with type 2 diabetes mellitus (T2DM).  While the glucagon-like peptide-1 (GLP-1) receptor agonists improve glycemic control, renal, and cardiovascular outcomes and induce significant weight loss, drugs that target more than one incretin hormone may have even greater therapeutic benefits.

Guest Authors: Nadila Faridi, PharmD and Kathleen Pincus, PharmD, BCPS, BCACP

Special Guest: Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES

Music by Good Talk